New York, New York (PRWEB) June 20, 2013
As a key researcher in the areas of protein folding and misfolding, Navneet Tyagi has remained closely linked to neurodegenerative diseases, including ALS and Alzheimer’s disease. Throughout the myriad of scientific research that Tyagi has participated in, he has held steady to his commitment of identifying early onset of these severe and mysterious neurological conditions. It is his hope that through early diagnosis, more medical researchers will be able to understand about the nature of conditions, such as Alzheimer’s, and potentially discover new avenues for progressive treatment or even a cure.
For this reason, Navneet Tyagi commends new developments of Alzheimer’s diagnostic procedures highlighted in a recent MSN article. The article focuses on an eye test that has been used in clinical setting to detect the presence of Alzheimer’s disease in patients. MSN explains, “A new study will trial an American-developed NeuroVision test aimed at detecting people at risk of developing Alzheimer's disease. Dr. Lance Macaulay from CSIRO said recent research showed Alzheimer's disease developed slowly.” According to Macaulay, up until recently it has only been understood that detection of Alzheimer’s disease is only possible when the condition has reached later stages in patients.
Fortunately, new advancements in eye scanning tests could help provide earlier detection of this condition. MSN reports, “…with a positron emission tomography (PET) scan, plaque build-up in the brain could be detected 17 years before symptoms appeared.” Even more importantly, if successful, the PET scan could be implemented as a non-invasive and affordable test to help identify those who may be developing Alzheimer’s disease. For Navneet Tyagi, earlier research opens up new opportunities for attempting new treatments.
“Since Alzheimer’s disease diagnoses usually come much later—once the condition has progressed—available treatments and their results are really hard to track and study, especially in terms of offering recovery or a cure to patients. With earlier detection, researchers may be able to implement new solutions and studies to see if there is a way to attack this neurodegenerative disease during its earlier phases.”
According to MSN, there are trials of how the PET scan may be used for diagnosing Alzheimer’s disease in patients. “It is very encouraging to see that medical researchers are thinking outside of the box to determine ways to understand the body as a whole and use different resources to determine the presence of other potential problems. For instance, doctors being able to detect neurological issues through a patient’s eye health. If this test does prove accurate, think of how many people could become aware of their Alzheimer’s development with a simple eye test, and thus, be able to receive treatment earlier on—it could even save their lives one day,” Navneet Tyagi concludes.
Navneet Tyagi is a scientist and researcher who has worked extensively in the areas of protein folding and misfolding, and the roles of different molecular chaperones in neurodegenerative diseases like ALS, Parkinson’s, and Alzheimer’s. He also worked on the identification of early childhood onset neurodegenerative diseases. His previous findings on the sodium/D-glucose cotransporter protein have proven highly influential in the ongoing development of diabetes treatments. Tyagi was educated in India and received his PhD in Germany.